Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy
Novo Nordisk A/S (NYSE: NVO) announced the market launch of Wegovy (semaglutide) oral tablets in...
Metabolic disease
China‑SCO Metabolic Disease Cooperation Center Established at Ruijin Hospital – First National‑Level SCO Platform in Shanghai
The China‑Shanghai Cooperation Organization (SCO) Metabolic Disease Cooperation Center was officially established at Ruijin Hospital,...
United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
United Laboratories International Holdings Ltd (HKG: 3933) announced completion of a Phase II clinical trial for...
Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
Novo Nordisk (NYSE: NVO) announced that, effective January 1, 2027, it will lower Wholesale Acquisition Cost (list prices)...
Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly
Novo Nordisk A/S (NYSE: NVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting...
Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a landmark partnership with AstraZeneca Plc (AZ, NASDAQ: AZN) to...
Insilico Medicine Partners with Qilu Pharma on AI Drug Development
Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...
Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND
Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP‑1R/GIPR/GCGR...
Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management
Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...
CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...
SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases
SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...